Aldeyra Therapeutics
ALDX
119 hedge funds and large institutions have $328M invested in Aldeyra Therapeutics in 2023 Q2 according to their latest regulatory filings, with 41 funds opening new positions, 34 increasing their positions, 27 reducing their positions, and 30 closing their positions.
37% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 30
26% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 27
10% more funds holding
Funds holding: 108 → 119 (+11)
5.92% more ownership
Funds ownership: 60.72% → 66.64% (+5.9%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
7% less capital invested
Capital invested by funds: $353M → $328M (-$25.8M)
38% less call options, than puts
Call options by funds: $5.55M | Put options by funds: $8.91M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$28.3M |
| 2 |
BlackRock
New York
|
+$22.1M |
| 3 |
KCM
Knoll Capital Management
Miami,
Florida
|
+$9.35M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.71M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$4.58M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$8.46M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$8.44M |
| 3 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
-$7.74M |
| 4 |
N
Natixis
Paris,
France
|
-$6.7M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$6.41M |
ALDX Hedge Fund Activity: Q2 2023 in Review
119 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Aldeyra Therapeutics (ALDX) for Q2 2023, worth a combined $328M — down 7.3% from $353M a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new ALDX positions and 30 closed out — a net gain of 11 holders — while 34 added to existing stakes and 27 trimmed.
The largest buyer was State Street, adding an estimated $28.3M. The largest seller was Morgan Stanley, cutting an estimated $8.46M.
- 119 institutional investors held Aldeyra Therapeutics (ALDX) as of Q2 2023, up from 108 in Q1 2023.
- Funds reported $328M of Aldeyra Therapeutics stock for Q2 2023, down 7.3% quarter-over-quarter.
- 41 funds opened new Aldeyra Therapeutics positions in Q2 2023 and 30 closed out, a net change of +11 holders.
- The largest Aldeyra Therapeutics buyer in Q2 2023 was State Street, an estimated $28.3M added.
- The largest Aldeyra Therapeutics seller in Q2 2023 was Morgan Stanley, an estimated $8.46M sold.
Based on aggregated 13F filings for Q2 2023.